Literature DB >> 28009703

Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch-induced activation.

Sheryl E Koch1, Adrien Mann, Shannon Jones, Nathan Robbins, Abdullah Alkhattabi, Mariah C Worley, Xu Gao, Valerie M Lasko-Roiniotis, Rajiv Karani, Logan Fulford, Min Jiang, Michelle Nieman, John N Lorenz, Jack Rubinstein.   

Abstract

OBJECTIVE: Hypertension (increased afterload) results in cardiomyocyte hypertrophy leading to left ventricular hypertrophy and subsequently, heart failure with preserved ejection fraction. This study was performed to test the hypothesis that transient receptor potential vanilloid 2 subtype (TRPV2) function regulates hypertrophy under increased afterload conditions.
METHODS: We used functional (pore specific) TRPV2 knockout mice to evaluate the effects of increased afterload-induced stretch on cardiac size and function via transverse aortic constriction (TAC) as well as hypertrophic stimuli including adrenergic and angiotensin stimulation via subcutaneous pumps. Wild-type animals served as control for all experiments. Expression and localization of TRPV2 was investigated in wild-type cardiac samples. Changes in cardiac function were measured in vivo via echocardiography and invasive catheterization. Molecular changes, including protein and real-time PCR markers of hypertrophy, were measured in addition to myocyte size.
RESULTS: TRPV2 is significantly upregulated in wild-type mice after TAC, though not in response to beta-adrenergic or angiotensin stimulation. TAC-induced stretch stimulus caused an upregulation of TRPV2 in the sarcolemmal membrane. The absence of functional TRPV2 resulted in significantly reduced left ventricular hypertrophy after TAC, though not in response to beta-adrenergic or angiotensin stimulation. The decreased development of hypertrophy was not associated with significant deterioration of cardiac function.
CONCLUSION: We conclude that TRPV2 function, as a stretch-activated channel, regulates the development of cardiomyocyte hypertrophy in response to increased afterload.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28009703     DOI: 10.1097/HJH.0000000000001213

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  12 in total

1.  Tranilast Blunts the Hypertrophic and Fibrotic Response to Increased Afterload Independent of Cardiomyocyte Transient Receptor Potential Vanilloid 2 Channels.

Authors:  Sheryl E Koch; Michelle L Nieman; Nathan Robbins; Samuel Slone; Mariah Worley; Lisa C Green; Yamei Chen; Alexandria Barlow; Michael Tranter; HongSheng Wang; John N Lorenz; Jack Rubinstein
Journal:  J Cardiovasc Pharmacol       Date:  2018-07       Impact factor: 3.105

2.  Structural mechanisms of TRPV2 modulation by endogenous and exogenous ligands.

Authors:  Nannan Su; Wenxuan Zhen; Heng Zhang; Lingyi Xu; Yitian Jin; Xiaoying Chen; Cheng Zhao; Qinrui Wang; Xinyan Wang; Shaowei Li; Han Wen; Wei Yang; Jiangtao Guo; Fan Yang
Journal:  Nat Chem Biol       Date:  2022-09-26       Impact factor: 16.174

Review 3.  Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.

Authors:  David Aluja; Sara Delgado-Tomás; Marisol Ruiz-Meana; José A Barrabés; Javier Inserte
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

4.  Developmental and lifelong dioxin exposure induces measurable changes in cardiac structure and function in adulthood.

Authors:  Matthew de Gannes; Sheryl E Koch; Alvaro Puga; Jack Rubinstein
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

5.  Arrhythmogenesis in the aged heart following ischaemia-reperfusion: role of transient receptor potential vanilloid 4.

Authors:  Deborah Peana; Luis Polo-Parada; Timothy L Domeier
Journal:  Cardiovasc Res       Date:  2022-03-16       Impact factor: 13.081

Review 6.  Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.

Authors:  Yuko Iwata; Tsuyoshi Matsumura
Journal:  Int J Mol Sci       Date:  2019-08-07       Impact factor: 5.923

Review 7.  Transient receptor potential channels in cardiac health and disease.

Authors:  Thomas Hof; Sébastien Chaigne; Alice Récalde; Laurent Sallé; Fabien Brette; Romain Guinamard
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

8.  Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro.

Authors:  Nathan Robbins; Mark Gilbert; Mohit Kumar; James W McNamara; Patrick Daly; Sheryl E Koch; Ginger Conway; Mohamed Effat; Jessica G Woo; Sakthivel Sadayappan; Jack Rubinstein
Journal:  J Am Heart Assoc       Date:  2018-01-13       Impact factor: 5.501

9.  Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.

Authors:  Evan Onusko; Michael R McDermott; Nathan Robbins; Guansheng Liu; Evangelia G Kranias; Jack Rubinstein; Sheryl E Koch
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240

Review 10.  Ca2+ Signaling in Cardiac Fibroblasts and Fibrosis-Associated Heart Diseases.

Authors:  Jianlin Feng; Maria K Armillei; Albert S Yu; Bruce T Liang; Loren W Runnels; Lixia Yue
Journal:  J Cardiovasc Dev Dis       Date:  2019-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.